{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-094433","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2026-08-12T10:59:47+00:00","discovered_at":"2026-08-12T11:05:00.426044+00:00","generated_at":"2026-08-12T11:05:38.385576+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protalix Q2 2026: YTD revenue $53.6M, net income $22.1M; Elfabrio patent extended to 2035","bullets":["Q2 goods revenue $19.8M, up $4.4M YoY on Elfabrio sales; YTD total revenue $53.6M vs $25.8M in 2025","Year-to-date net income $22.1M, achieving profitability; cash and short-term deposits $40.7M at June 30, 2026","FY2026 revenue guidance reaffirmed at $78-83M incl. $25M Chiesi milestone; Elfabrio $33-35M, Elelyso $20-23M","USPTO extended Elfabrio US patent to Nov 17, 2035 (May 4, 2026); South Korea orphan drug designation + MA granted May 2026","PRX-115 Phase 2 RELEASE enrollment ongoing; top-line results expected H2 2027; USPTO issued uricase patent July 7, 2026"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-094433","json":"https://secwatch.observer/filing/0001104659-26-094433.json","markdown":"https://secwatch.observer/filing/0001104659-26-094433.md","text":"https://secwatch.observer/filing/0001104659-26-094433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926094433/0001104659-26-094433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926094433/plx-20260812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T11:05:38.385576+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}